Epilepsy Drug Linked to Birth Defects, Low IQ
Evidence Continues to Mount Against Valproate
March 21, 2005 -- The evidence continues to mount against the use of the antiseizure drug valproate during pregnancy.
In two new studies, children born to mothers who took valproate during early pregnancy had higher rates of birth defects and lowered verbal IQ.
A newer epilepsy medication, Lamictal, studied in a third trial found no such risk.
These studies join a least a half dozen others implicating epilepsy expert tells WebMD that the findings are convincing.
"When you put all of these trials together it is clear that women in their childbearing years should not be using valproate unless there is an absolute need," neurologist Jacqueline French, MD, tells WebMD.
Valproate Very Popular
Valproate, sold under the brand names Depakote, Depakene, and Depacon, is one of the oldest and most widely prescribed antiseizure medications on the market.
In one of the newly published studies, one in 10 children born to women who took valproate had birth defects.
Researcher Diego Wyszynski and colleagues followed 149 women enrolled in a national registry of pregnancy outcomes among users of antiseizure drugs.
The risk of delivering a child with a birth defect was three times higher for women who took valproate during their first trimester of pregnancy than for women taking other antiseizure medications. The risk among valproate users was seven times greater than among the general population.
A study from the U.K. examined IQ scores among children whose mothers took antiseizure drugs while pregnant. A total of 249 children between the ages of 6 and 16 were enrolled in the trial.
Investigators reported that children exposed to valproate in the womb were significantly more likely to have low verbal IQ scores than children exposed to the antiseizure drug Dilantin or children whose mothers took no epilepsy drugs.
Valproate-exposed children were also more likely to have overall IQ scores in the extremely low or mentally impaired range, with 22% falling into this range compared with about a 3% rate in the general population.
No Increase Seen With Lamictal
Finally, a third study examined birth defects among children born to mothers who took the newer epilepsy drug Lamictal.